Discussion about this post

User's avatar
Russ Hollyer's avatar

Absolutely true—and it's a core principle of how I approach things as well. My medical oncologist trained at Moffitt, so she’s not just ahead of the curve—she’s light years ahead.

I simulated predicted results (assuming I was a moderate responder which from my genomic makeup appears likely) and the output floored me. Showed a distinct rise in PSA as populations jockey for position, then a leveling off, then a plunge. I watched the rise, the level, and now I've been going through the plunge for almost two years. The simulation predicted a PSA of 0.13 at year ten. It's only been four and I'm at 0.17. At the rate of decrease, I hope to be less than 0.13 in a month or two.

Per SOC I should have been CRPC years ago. I'm still HSPC with a zero tumor burden, a dropping PSA, an undefined PSADT, and a negative PSAV. And I have to add, the side effects? So good I'll do this even if my MO declares me cured.

"The poorly differentiated, low-PSA cancer cells are like hardened criminals armed with deadly weapons, whereas the high-PSA–producing cells resemble civilians wielding only sticks and knives. Over time, the criminals band together and even recruit the civilians, arming them with the same lethal tools.

Our goal is a population composed largely of those “civilians,” so eradicating them all is counterproductive. Equally unwise is weakening the civilians to the point that the criminals can easily conscript them. Instead, we aim to regulate the civilians’ modest armaments—allowing only pocket-knife level force—while neutralizing the criminals’ arsenals.

"

Four-Group Classification System

Understanding tumor heterogeneity is essential for aBAT optimization:

Group A: External DHT–Dependent Cells

• Androgen Sensitivity: Rely on circulating DHT for survival; they undergo rapid apoptosis under standard ADT while secreting the majority of PSA, making them reliable biomarkers of therapeutic response.

• Competitive Suppression: Maintaining a residual population preserves competitive pressure that restrains expansion of resistant clones.

• aBAT Targeting: Supraphysiologic testosterone pulses exploit high AR expression to induce TOP2B-mediated DNA double-strand breaks and preferential cell death in this group.

Group B: AR-Upregulated DHT–Dependent Cells

• AR Overexpression: Elevated AR levels sensitize these cells to SPA, situating them between hormone-sensitive and fully resistant phenotypes.

• Transitional Phenotype: They retain partial sensitivity to ADT or ARSIs but are vulnerable to SPA-induced cytotoxicity.

• Dual-Phase Targeting: aBAT’s alternating high- and low-testosterone phases combine SPA toxicity with subsequent AR blockade (typically using darolutamide) to prevent full resistance emergence.

Group C: Internal DHT–Producing Cells

• Intratumoral Steroidogenesis: Convert adrenal precursors (DHEA, DHEAS, androstenedione) into DHT, sustaining growth despite systemic androgen deprivation.

• ARSI Integration: Rather than abiraterone, aBAT protocols reinstate an ARSI (e.g., darolutamide) during the low-testosterone phase to suppress both circulating and intratumoral androgen signaling.

• aBAT Strategy: Pulsed SPA peaks followed by low-T ARSI phases suppress de novo androgen production while reintroducing competitive, hormone-sensitive cells to maintain tumor control.

Group D: Adaptive/Plastic Cells

• Phenotypic Plasticity: Can switch dynamically between androgen-dependent and independent states under sustained therapy pressure, representing a reservoir for adaptive resistance.

• Resistance Reservoir: Intermediate molecular features confer robust resistance, allowing survival through both hormonal extremes.

• Non-Hormonal Interventions: Often require local therapies (radiation, metastasis-directed SBRT) or immunotherapy for eradication.

• aBAT Strategy: Impose rapid cycles of supraphysiologic androgen exposure followed by deep suppression, thereby destabilizing transcriptional programs that sustain plasticity and forcing cells toward committed states that are more therapy-sensitive

• Experimental Concept: A single ultra-high androgen pulse administered concurrently with an ARSI (e.g., darolutamide during SPA) might destabilize plasticity programs. This hypothesis is novel and remains untested in clinical settings.

The poorly differentiated, low-PSA cancer cells are like hardened criminals armed with deadly weapons, whereas the high-PSA–producing cells resemble civilians wielding only sticks and knives. Over time, the criminals band together and even recruit the civilians, arming them with the same lethal tools.

Our goal is a population composed largely of those “civilians,” so eradicating them all is counterproductive. Equally unwise is weakening the civilians to the point that the criminals can easily conscript them. Instead, we aim to regulate the civilians’ modest armaments—allowing only pocket-knife level force—while neutralizing the criminals’ arsenals.

Chart of theoretical population changes.

Overall, Population C (androgen-independent) undergoes a steep decline from 120 million to under 1 million cells by year 10, reflecting effective long-term suppression of resistant clones. Population A (androgen-dependent) and Population B (testosterone-producing) initially recover during the adaptation phase and then decline as competitive dynamics stabilize. Population D (adaptive/plastic) remains at minimal levels throughout the decade, indicating limited phenotypic switching under optimized cycling. PSA levels, plotted on the secondary axis, mirror these population shifts by rising modestly during cell recovery phases and then declining steadily, reaching 0.13 ng/mL at year 10.

Expand full comment

No posts